Transplantation of allogenic cells in the therapy of patients with dilated cardiomyopathy

Кириллов, А М; Fatkhudinov, Timur; Dyachkov, A.; Коротеев, А В; Goldshtein, D. V.; Бочков, Н. П.

doi:10.1007/s10517-007-0392-4

Cited by 11 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A benefit from cell therapies is corroborated by many studies where clinical or functional improvement has been reported [6] . At the same time, there is a gap between advertising and a more fundamental part of the scientific literature: the former speaks about rejuvenation of tissues etc., and the latter explains sometimes questionable therapeutic effects by paracrine or immunomodulating mechanisms via secretion of cytokines or growth factors [5,7] .…”

mentioning

confidence: 85%

Stem Cells and Cell Therapy

Jargin¹

2010

Cardiology

View full text Add to dashboard Cite

mentioning

confidence: 85%

Stem Cells and Cell Therapy

Jargin¹

2010

Cardiology

View full text Add to dashboard Cite

“…No similar reports have been found in the international literature. Finally, intravenous injections of stem cells to Tb patients should be mentioned together with the warning against unjustified use of Bs for such purposes as it has previously been done concerning intracoronary injections of cells obtained from the abortion material [108][109][110][111][112].…”

Section: Repeated Hemoptysis or Secondary Infectionmentioning

confidence: 99%

Some Aspects of the Surgical and Endoscopic Treatment of Tuberculosis in Russia

2021

J Surg

View full text Add to dashboard Cite

26,000, while 85% of the operations were lung resections [6]. In the period 1986-1988, 17,000-18,000 operations for pulmonary Tb were performed in Russia yearly only in specialized tuberculosis hospitals [3]. In 2003, 10,479 surgeries were performed in Russia for respiratory Tb, which was deemed "extremely insufficient" [7]. In 2006, 12,286 operations were carried out for pulmonary Tb including 9300 (75.7%) lobectomies and other resections as well as 399 (3.2%) pneumonectomies [4]. According to another report, the forms of Tb most frequently treated by resections and pneumonectomies were cavitary Tb (52.2%) and tuberculoma (43.9%) [8].The abovenamed surgeries were performed and recommended also for patients with inactive post-tuberculous fibrosis including cases with sparse symptoms [9]. At the same time, surgeries were performed in the active phase of Tb. In some provinces (Kemerovo, Chelyabinsk, Mordovia), 25-40% of patients with destructive Tb were operated on [10]. At the time of initial Tb diagnosis, an operation was deemed reasonable in 15-20% of patients [3]. According to another paper by the same authors, indications for surgery were found in 20-30% of patients at the initial diagnosis and/or among cases of active Tb [11].In Yekaterinburg and surrounding province (2006)(2007)(2008), indications for surgery were determined in 1784 from 4402 (40.5%) patients with pulmonary Tb while 1079 (24.5%) were operated on. Among reasons of the comparatively "low" surgery rate were the patients' non-compliance and unavailability [12]. In the international literature, corresponding figures are generally lower e.g. <5% of pulmonary Tb patients were supposed to require surgery [13]. The same percentage is given in the reviews [14,15]. The topic of Tb surgery may become more relevant due to the multidrug resistance. According to a current estimate from Russia, the need for surgery has increased from 5% to 15% over the last twenty years [16]. However, the recent systematic review and metaanalysis concluded that, compared with chemotherapy alone, the survival benefit of pulmonary resection combined with chemotherapy is not significant, although the quality of data was deemed "relatively poor" [17]. According to another metaanalysis, partial lung resection, but not pneumonectomy, was associated with improved treatment success in multidrug-resistant Tb. It was not excluded, however, that "healthier" patients were preferentially chosen for surgery, leading to a bias. The confounding by indication, as patients most likely to benefit are selected for the treatment, has been a limitation in many

show abstract

“…15 Finally, a clinical study limited to one patient presenting with idiopathic DCM reported improved cardiac function and increased incidence of arrythmias upon injection of autologous Mb at the time of mitral valvuloplasty. 42 In the present study, we used the D7LNB1 cells as our source of Mb for practical and conceptual reasons. Because of their clonal origin, the D7LNB1 cells are purely myogenic, and the preparations do not present the heterogeneity and variability encountered in primary cell cultures.…”

Section: Mb Transplantation In Dcmmentioning

confidence: 99%

Myoblasts and Embryonic Stem Cells Differentially Engraft in a Mouse Model of Genetic Dilated Cardiomyopathy

et al. 2013

View full text Add to dashboard Cite

The functional and architectural benefits of embryonic stem cells (ESC) and myoblasts (Mb) transplantations into infarcted myocardium have been investigated extensively. Whereas ESC repopulated fibrotic areas and contributed to myocardial regeneration, Mb exerted their effects through paracrine secretions and scar remodeling. This therapeutic perspective, however, has been less explored in the setting of nonischemic dilated cardiomyopathies (DCMs). Our aim was to compare the integration and functional efficacy of ESC committed to cardiac fate by bone morphogenic protein 2 (BMP-2) pretreatment and Mb used as gold standard following their transplantation into the myocardium of a mouse model of laminopathy exhibiting a progressive and lethal DCM. After 4 and 8 weeks of transplantation, stabilization was observed in Mb-transplanted mice (P = 0.008) but not in groups of ESC-transplanted or medium-injected animals, where the left ventricular fractional shortening (LVFS) decreased by 32 ± 8% and 41 ± 8% respectively. Engrafted differentiated cells were consistently detected in myocardia of mice receiving Mb, whereas few or no cells were detected in the hearts of mice receiving ESC, except in two cases where teratomas were formed. These data suggest that committed ESC fail to integrate in DCM where scar tissue is absent to provide the appropriate niche, whereas the functional benefits of Mb transplantation might extend to nonischemic cardiomyopathy.

show abstract

Transplantation of allogenic cells in the therapy of patients with dilated cardiomyopathy

Cited by 11 publications

References 12 publications

Stem Cells and Cell Therapy

Stem Cells and Cell Therapy

Some Aspects of the Surgical and Endoscopic Treatment of Tuberculosis in Russia

Myoblasts and Embryonic Stem Cells Differentially Engraft in a Mouse Model of Genetic Dilated Cardiomyopathy

Contact Info

Product

Resources

About